{"id":4298,"date":"2026-11-13T09:00:00","date_gmt":"2026-11-13T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4298"},"modified":"2026-11-14T12:48:15","modified_gmt":"2026-11-14T16:48:15","slug":"cellectis-details-in-vivo-editing-reorganization","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4298","title":{"rendered":"Cellectis Details In Vivo Editing Reorganization"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"393\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Cellectis_Technology_and_Modalities-768x393.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4321\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Cellectis_Technology_and_Modalities-768x393.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Cellectis_Technology_and_Modalities-300x154.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Cellectis_Technology_and_Modalities-1024x524.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Cellectis_Technology_and_Modalities-1536x786.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Cellectis_Technology_and_Modalities.png 1752w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Cellectis<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Reorganization update and preclinical data<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>In vivo base editing and epigenetic silencing (LNP-mRNA)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>.HEAL-101 (APOC3); .HEAL-201 (PCSK9)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>APOC3; PCSK9<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Severe hypertriglyceridemia; severe hypercholesterolemia<\/p>\n<h4>Summary<\/h4>\n<p>Cellectis reported further operating consequences of its previously announced shift to in vivo editing: enrollment in its lasme-cel and eti-cel programs has stopped, and global headcount may fall by up to 70% from the pre-transition level during 2026\u20132027. It also supplied expanded preclinical data for liver-directed APOC3 and PCSK9 programs.<\/p>\n<p>The company release is dated November 13, with a New York dateline of November 12. .HEAL-101, an LNP-mRNA APOC3 base editor, achieved mean 65% editing of human APOC3 in a humanized liver mouse model, up to 70%, and mean triglyceride reduction of 75% \u00b1 11% in a separate transgenic disease model. .HEAL-201, a TALE-based epigenetic PCSK9 silencer, reduced plasma PCSK9 by more than 90% in a liver-humanized mouse model. Cellectis expects a China investigator-initiated .HEAL-101 study and preliminary data in H2 2027. The transformation itself was announced September 14; the quantified workforce plan and program-closeout status are the current update.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> concentration of resources may extend runway and sharpen an in vivo pipeline, supported by the stated $149 million September 30 cash and targeted H2 2028 runway.<\/p>\n<p><strong>Interpretation B:<\/strong> extensive workforce reduction and cessation of clinical programs may impair execution capacity or partner delivery; the planned magnitude and loss of clinical assets support this concern. Neither inference proves improved financing health or future clinical success. The APOC3 and PCSK9 signals are target-engagement and lipid-biomarker findings in different animal models, not human therapeutic evidence. Liver restriction was observed only in sampled tissues; genome-wide off-target, germline, immunogenicity and long-term durability remain open. French consultation and labor-law processes can change timing or scale.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Cellectis is a gene-editing company. Lasme-cel and eti-cel were allogeneic edited CAR T candidates. .HEAL-101 aims to disrupt hepatic APOC3 to lower triglycerides in severe hypertriglyceridemia; .HEAL-201 aims to suppress hepatic PCSK9 transcription without changing DNA sequence for severe hypercholesterolemia.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Signal: sizeable platform and portfolio reallocation plus a quantifiable workforce plan.<\/li>\n<li>Missing: finalized staffing by function, partner obligations, human editing and durability, and full toxicology.<\/li>\n<li>Upgrade: preserved program and partner milestones plus reproducible human target engagement.<\/li>\n<li>Downgrade or falsify: delayed trial initiation, manufacturing bottlenecks, or safety findings that narrow the liver-editing window.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The preclinical pharmacology justifies continued translation, while the near-term operational effect is a material contraction. The release does not establish that the new model will outperform the discontinued allogeneic CAR T programs.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: mixed. Confidence in Facts: high for company-disclosed actions and animal results. Confidence in Interpretation: moderate for execution implications and low for clinical efficacy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cellectis reported further operating consequences of its previously announced shift to in vivo editing: enrollment in its lasme-cel and eti-cel programs has stopped, and global headcount may fall by up to 70% from the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4321,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1478,750,1477],"class_list":["post-4298","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-apoc3","tag-cellectis","tag-in-vivo-editing"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4298"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4298\/revisions"}],"predecessor-version":[{"id":4323,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4298\/revisions\/4323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4321"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}